GoodRx Holdings (GDRX) Accumulated Expenses (2019 - 2026)

GoodRx Holdings has disclosed Accumulated Expenses across 8 years of filings, most recently posting $83.7 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $83.7 million, up 7.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $83.7 million (up 7.93% YoY), and the FY2025 annual result was $86.7 million, up 4.05% from the prior year.
• Accumulated Expenses came in at $83.7 million for Q1 2026 at GoodRx Holdings, down from $86.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $143.4 million in Q3 2025 to a low of $33.8 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $73.2 million (2024), against an average of $74.0 million.
• Peak annual rise in Accumulated Expenses reached 206.74% in 2022, while the deepest fall reached 3.24% in 2022.
• GoodRx Holdings' Accumulated Expenses stood at $47.5 million in 2022, then surged by 50.09% to $71.3 million in 2023, then climbed by 16.83% to $83.3 million in 2024, then advanced by 4.05% to $86.7 million in 2025, then dropped by 3.44% to $83.7 million in 2026.
• The last three Accumulated Expenses figures came in at $83.7 million (Q1 2026), $86.7 million (Q4 2025), and $143.4 million (Q3 2025), per Business Quant data.